X4 Pharmaceuticals (XFOR) Cash from Investing Activities (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Cash from Investing Activities for 10 consecutive years, with -$1.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities fell 104.33% year-over-year to -$1.0 million; the trailing twelve-month figure through Jun 2026 stood at $6.4 million (up 240.56% YoY), and the FY2025 full-year result was $8.2 million, down 87.83% from the prior year.
• Cash from Investing Activities retreated to -$1.0 million in Q2 2026 per XFOR's latest filing, from $19.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $96.9 million in Q2 2024 and bottomed at -$28.7 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged $4.4 million across 5 years, with a median of -$519000.0 in 2022.
• The widest YoY moves for Cash from Investing Activities: up 2083.25% in 2024, down 59033.33% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$34000.0 in 2022, then slumped by 14114.71% to -$4.8 million in 2023, then sank by 78.38% to -$8.6 million in 2024, then surged by 295.44% to $16.8 million in 2025, then slumped by 105.94% to -$1.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.0 million, $19.3 million, and $16.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.